Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Short-Term Debt issuances (2019 - 2020)

Zevra Therapeutics (ZVRA) has disclosed Short-Term Debt issuances for 2 consecutive years, with $1.2 million as the latest value for Q2 2020.

  • For the quarter ending Q2 2020, Short-Term Debt issuances fell 3.09% year-over-year to $1.2 million, compared with a TTM value of $1.2 million through Sep 2021, down 48.28%, and an annual FY2020 reading of $2.3 million, down 57.71% over the prior year.
  • Short-Term Debt issuances was $1.2 million for Q2 2020 at Zevra Therapeutics, up from $1.1 million in the prior quarter.
  • Across five years, Short-Term Debt issuances topped out at $2.7 million in Q1 2019 and bottomed at $1.1 million in Q1 2020.